Problematika rezistence Helicobacter pylori k antimikrobním léčivům

Klin Farmakol Farm. 2004;18(3):142-143

Problematika rezistence Helicobacter pylori k antimikrobním léčivům

MUDr. Jindra Lochmannová jr¹, doc. MUDr. Milan Kolář PhD², doc. MUDr. Otto Lochmann CSc³: ¹ Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze; ² Ústav mikrobiologie FN a LF UP v Olomouci; ³ emeritní docent Ústavu mikrobiologie 2. LF UK, Praha

Keywords: Helicobacter pylori, antibiotics, resistance, therapy.

Published: December 31, 2004 Show citation

Lochmannová J, Kolář M, Lochmann O. Problematika rezistence Helicobacter pylori k antimikrobním léčivům. Klin Farmakol Farm. 2004;18(3):142-143.

Práce je věnována problematice rezistence Helicobacter pylori k antibiotikům. Je diskutován způsob testování rezistence na antibiotika (E-test, fluorescenční metoda, molekulárně genetické postupy) a možnosti antibiotické léčby.

V našem souboru byly zjištěny značné rozdíly v rezistenci ke klaritromycinu (< 5 %) a metronidazolu, kde rezistence činila více než 40 %. Na základě výsledků lze jako léčbu I. volby u infekcí způsobených H. pylori doporučit spíše kombinaci klaritromycinu s amoxicilinem a omeprazolem.

RESISTANCE OF HELICOBACTER PYLORI TO ANTIBIOTICS

The paper deals with resistance of Helicobacter pylori to antibiotics. Special attention is paid to H. pylori resistance testing to antibiotics (E-test, fluorescence method, molecular-genetic procedures) and possibilities of antibiotic treatment.

Our experimental set demonstrated significant differences in resistance to clarithromycin (< 5 %) and metronidazole (above 40 %). Based on the results of our study it may be recommended to use the combination of clarithromycin with amoxicillin and omeprazol as the first option therapy.

References

Martínek J, Špičák J. Onemocnění žaludku a dvanáctníku. Triton, Praha, 2000.
Hynie S. Farmakologie v kostce. Triton, Praha, 1999.
Hynie S. Speciální farmakologie. Karolinum, Praha, 2002.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelth informational supplement. NCCLS, 2002.
Boyanova L. Status of H. pylori resistance in the east of Evrope. Clin Microbiol Infect 2001;7:28-31.
Samra Z, Shumely H, Niv Y, et al. Resistance of Helicobacter pylori isolates to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime in patients after treatment failure. Clin Microbiol Infect 2003; 9:8-12.
Chatsuman T, Paton F, Heading R, Amyes S. Antimicrobial susceptibilities and mechanisms of macrolide and fluoroquinolone resistance in Helicobacter pylori isolated in Scotland. Abstract C2-61, 41th ICAAC, Chicago 2001; p. 112.
Arents N, Thijs J, Van Zwet A, Kleibeuker J. A six-year surveillance of Helicobacter pylori resistance to metronidazole and clarithromycin in a large study population in the Netherlands. Abstract C2-1319, 41th ICAAC, Chicago 2001; p. 136.
Glupczynski Y, Nizet H, Berthin C, et al. Prevalence of primary antibiotic resistance in Helicobacter pylori at two different locations in Belgium. Clin Microbiol Infect 2003; 9:14-17.
Elviss NC, Owen RJ, Teare EL, Brathnach A, Shety N. Development of antibiotic resistance surveillance for Helicobacter pylori infecting dyspeptics in south-east England -a review of progress. Clin Microbiol Infect 2001; 7: 71-73.
Allarcon T, Domingo D, Martinez M, Garcia J, Lopz-Brea M. High level clarithromycin resistance in Helicobacter pylori from pediatric patients. Abstract G1557, 41th ICAAC, Chicago 2001; p.271.
Rozynek E, Dzierzanowska-Fangrat D, Celinska-Cedro P, Jozwiak P, Dzierzanowska D. Analysis of primary resitance to clarithromycin of Helicobacter pylori strains isolated from children. Clin Microbiol Infect 2001; 7:131-134.
De La Obra Sanz P, Hernandez J, Martinez M, Alarcon T, Lopez-Brea M. Prevalence of antimicrobial resistance in Helicobacter pylori clinical strains. Clin Microbiol Infect 2002; 8:98-101.